Joseph Auxier, DO
Pulmonary Disease · Fremont, NENPI 1760409445
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,012 of the $8,623 with a category attached, or 81.3%. Intuitive Surgical accounts for 92.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $8,029, more than ten times the $289 reported in 2019.
Across 52 payments — averaging $165.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Boehringer Ingelheim$131
- Philips North America LLC$81
- GSK$74
- AstraZeneca$50
- E.r. Squibb & Sons, L.L.C.$40
- plus $237 from 9 others
What the payments were for
- Travel & lodging$99412%
- Food & beverage$6187%
- Education$7,01281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $8,011 |
| Boehringer Ingelheim | 11 | $131 |
| Philips North America LLC | 4 | $81 |
| GSK | 6 | $74 |
| AstraZeneca | 4 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Genentech USA, Inc. | 3 | $38 |
| Sanofi | 2 | $38 |
| Insmed, Inc. | 2 | $30 |
| Electromed, Inc. | 2 | $25 |
| Mylan Specialty L.p. | 2 | $23 |
| Grifols USA, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,975
How this compares
$8,623 in reported general payments places this provider in the 80th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 458 | $358,033 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $273,612 |
| Dupixent PenDupilumab | 30 | $136,501 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 135 | $78,200 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $65,490 |
| Spiriva RespimatTiotropium Bromide | 82 | $57,884 |
| Dupixent SyringeDupilumab | 13 | $49,857 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $41,475 |
| SymbicortBudesonide/Formoterol Fumarate | 103 | $29,956 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $24,315 |
| Spiriva HandihalerTiotropium Bromide | 30 | $18,389 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $17,613 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 159 | $17,553 |
| Roflumilast | 78 | $7,167 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 255 | $6,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $74 | $501,143735 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $50 | $95,446186 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $131 | $82,199126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Fremont
- Ryan MartinLincoln$600K
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Michael SanleyOmaha$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.